Compare IDEXX Laboratories, Inc. (IDXX) vs Samsara Inc (IOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Samsara Inc — how do they compare? IDEXX Laboratories, Inc. trades at $572.1 (market cap $46.22B), while Samsara Inc trades at $39 (market cap $23.49B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Samsara Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | IOT | |
|---|---|---|
Market Cap | $46.22B | $23.49B |
Sector | Health | Technology |
52-Week High | $766.68 | $45.22 |
52-Week Low | $526.44 | $24.25 |
Enterprise Value | $47.12B | $22.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Samsara (IOT) trades at $39.11, down 1.88% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company shows impressive revenue growth, projecting $1.7B for 2026 with a positive net income turnaround to $58M. Recent earnings beats and a 'Moderate Buy' analyst consensus with a $44.50 price target highlight investor confidence in the Connected Operations Platform strategy.
Outlook remains positive with 36.9% upside potential to consensus targets, though elevated P/E ratio of 403.2 and negative 2025 EBITDA pose valuation risks. Key catalysts include continued AI adoption in physical operations and September earnings report, while competition and execution on growth investments represent primary challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →
